Current Valuation
N/A
As of August 30, 2024
Total Funding Raised
$4.2M
Last Round
Seed Round

Amount undisclosed

Last Funding
Aug 2024

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Lynx Biosciences is currently valued at N/A as of August 30, 2024. The company has raised a total of $4.2M in funding.

Investment Perspective

Lynx Biosciences's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Lynx Biosciences Valuation Updates

Get notified when Lynx Biosciences raises new funding or valuation changes

What is Lynx Biosciences Worth in 2025?

As of 2025, Lynx Biosciences is valued at N/A, based on the company's Seed Round funding round in August 30, 2024. This valuation positions Lynx Biosciences as one of the leading private companies in the sector.

Lynx Biosciences Valuation History

Lynx Biosciences's funding history demonstrates steady growth and investor confidence.

How Lynx Biosciences Valuation is Determined

Private company valuations like Lynx Biosciences's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Lynx Biosciences Valuation FAQs

Is Lynx Biosciences profitable?

Lynx Biosciences has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Lynx Biosciences's valuation compare to competitors?

Lynx Biosciences is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Lynx Biosciences IPO?

Lynx Biosciences has not announced plans for an initial public offering. Until an IPO, investors can access Lynx Biosciences shares through secondary market platforms.